Systemic Bevacizumab Treatment for Recurrent Respiratory Papillomatosis: Long-Term Follow-Up

Area of Science:

• Otolaryngology
• Pediatric Oncology
• Pharmacology

Background:

• Recurrent respiratory papillomatosis (RRP) is a rare disease often requiring repeated surgical debridement.
• Systemic bevacizumab has emerged as a potential adjuvant therapy for RRP, particularly in pediatric cases refractory to traditional treatments.

Purpose of the Study:

• To report the largest series to date evaluating the long-term efficacy and safety of systemic bevacizumab for pediatric RRP.
• To assess disease burden reduction and complication rates in children receiving bevacizumab therapy.

Main Methods:

• Retrospective chart review of seven pediatric patients with RRP.
• Patients received systemic bevacizumab for RRP refractory to debridement over a 6-year period.

Main Results:

• All seven patients demonstrated a significant reduction in RRP disease burden.
• The median treatment duration was 2.13 years, with three patients on therapy for over 3 years.
• No major complications were observed; one patient experienced recurrence upon discontinuation and was diagnosed with lung cancer.

Conclusions:

• Systemic bevacizumab is an effective long-term therapy for severe pediatric RRP with minimal side effects.
• Close patient monitoring is essential for optimizing dosage and screening for disease progression.